First Time Loading...

Design Therapeutics Inc
NASDAQ:DSGN

Watchlist Manager
Design Therapeutics Inc Logo
Design Therapeutics Inc
NASDAQ:DSGN
Watchlist
Price: 3.91 USD 9.52% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of DSGN.

Key Points:
DSGN Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Financials

Balance Sheet Decomposition
Design Therapeutics Inc

Current Assets 284.6m
Cash & Short-Term Investments 281.8m
Receivables 1.4m
Other Current Assets 1.4m
Non-Current Assets 5.1m
PP&E 4.6m
Other Non-Current Assets 430k
Current Liabilities 9.6m
Accounts Payable 1.9m
Accrued Liabilities 7.7m
Non-Current Liabilities 2.3m
Other Non-Current Liabilities 2.3m
Efficiency

Earnings Waterfall
Design Therapeutics Inc

Revenue
0 USD
Operating Expenses
-78.2m USD
Operating Income
-78.2m USD
Other Expenses
11.3m USD
Net Income
-66.9m USD

Free Cash Flow Analysis
Design Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DSGN Profitability Score
Profitability Due Diligence

Design Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Design Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

DSGN Solvency Score
Solvency Due Diligence

Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Design Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DSGN Price Targets Summary
Design Therapeutics Inc

Wall Street analysts forecast DSGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DSGN is 4.85 USD with a low forecast of 4.04 USD and a high forecast of 6.3 USD.

Lowest
Price Target
4.04 USD
3% Upside
Average
Price Target
4.85 USD
24% Upside
Highest
Price Target
6.3 USD
61% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DSGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DSGN Price
Design Therapeutics Inc

1M 1M
+37%
6M 6M
+62%
1Y 1Y
-29%
3Y 3Y
-89%
5Y 5Y
-80%
10Y 10Y
-80%
Annual Price Range
3.91
52w Low
1.99
52w High
8.14
Price Metrics
Average Annual Return -24.39%
Standard Deviation of Annual Returns 40.79%
Max Drawdown -95%
Shares Statistics
Market Capitalization 220.8m USD
Shares Outstanding 56 002 000
Percentage of Shares Shorted 8.47%

DSGN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Design Therapeutics Inc Logo
Design Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

220.8m USD

Dividend Yield

0%

Description

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.

Contact

CALIFORNIA
Carlsbad
6005 Hidden Valley Road, Suite 110
+18582934900.0
https://www.designtx.com/

IPO

2021-03-26

Employees

37

Officers

Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Mr. Pratik Shah Ph.D.
Chief Operating Officer
Dr. Sean Jeffries Ph.D.
Co-Founder & Scientific Advisor
Dr. Aseem Z. Ansari Ph.D.
Chief Accounting Officer
Ms. Julie D. Burgess CPA
Senior Vice President of Regulatory Affairs
Dr. Elizabeth Gordon Ph.D.
Chief Medical Officer
Dr. Jae B. Kim FACC, M.D.
Show More
Controller
Ms. Dawn Giangiulio
Show Less

See Also

Discover More